Navigation Links
Experienced Drug Development and Partnering CEO Takes the Helm at Tolera
Date:12/3/2013

KALAMAZOO, Mich., Dec. 3, 2013 /PRNewswire/ -- Tolera Therapeutics, Inc., a privately-held, immune therapy company developing a novel T-cell targeted therapeutic platform, announced today that it has appointed Ashleigh Palmer as President, CEO and Board Director.

Tolera's Chairman, Suzette Dutch, Managing Partner of Triathlon Medical Ventures, said, "Ashleigh has an ideal track record in developing, partnering and commercializing advanced-stage biopharma assets and pioneering therapeutic platforms.  The board is delighted with Ashleigh's appointment and is committed to supporting him as he evaluates and recommends Tolera's best path forward."

While taking the lead at Tolera, Mr. Palmer will continue as President of Creative BioVentures™ Corp., a strategic advisory serving the biopharma industry.  Since founding Creative BioVentures in 2002, Palmer has undertaken several challenging development-stage and turnaround assignments, including CEO and Chairman of Restoragen, Inc.; CEO of Canfite Biopharma, Ltd.; and CEO of Unigene Laboratories, Inc.

Previously, Palmer was Vice President of Business Development at Ohmeda, Inc., where he played an instrumental role in its $1.2 billion sale to a Baxter-led consortium by spinning out Ohmeda's inhaled nitric oxide assets to found INO Therapeutics, Inc.  Under Palmer's leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world's first selective pulmonary vasodilator, INOmax®, establishing an orphan drug franchise subsequently acquired by Ikaria for $670 million.

Earlier in his career, Palmer held positions of increasing responsibility in sales and marketing management at Reckitt Benckiser, PLC and SSL International, PLC.  He received his MBA from the University of Bradford, England and his BSc. honors in Biochemistry and Applied Molecular Biology from the University of Manchester, England.

"Having completed a successful Phase 2 renal transplantation study for its lead product candidate, TOL101, Tolera is now poised to carefully consider its strategic options, evaluate the needs of prospective partners, and advance this novel therapeutic approach towards a market that appears ripe for the entry of an advantageous induction agent," commented Palmer.  "Tolera also has a significant opportunity to advance its broader T-cell targeting therapeutic platform, especially with respect to autoimmune disease and cancer.  Effective partnering will be the key to this endeavor."

About Tolera Therapeutics   
Tolera Therapeutics is a biotechnology company focused on developing and commercializing a highly specific, T-cell antagonist, monoclonal antibody technology (anti-TCR) with application potential across a broad spectrum of T-cell mediated diseases, such as transplant rejection, autoimmune disease and cancer.  Its lead product candidate, TOL101, has to date successfully completed clinical testing through Ph2 and is ready to commence advanced stage clinical testing having received approval of a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial comparing TOL101 to Thymoglobulin.  Primary investors in the company include Triathlon Medical Venture Partners, Hopen Life Science Ventures, the SWMF Life Science Fund, and the Michigan Economic Development Corporation.  Additional information concerning the company and its technology can be found on its website www.tolera.com.

Media Contact: 
Jason Rando  
Tiberend Strategic Advisors, Inc. 
212.375.2665 
jrando@tiberend.com  


'/>"/>
SOURCE Tolera Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. ERT Acquires invivodata to Establish the Industrys Most Experienced Provider of Clinical Outcome Assessment Solutions
3. RxAlly Announces Addition Of Experienced Corporate Counsel Tom OGrady To The Companys Leadership Team
4. Safe in Common Offers Experienced Advice for U.K.s Review of Needlestick Safety Regulations
5. Survey of Oncologists Reveals 98.9% of Physicians Experienced Cancer Drug Shortages in Last 12 Months
6. Experienced Surgeon Vs. FDA-Approved Robot
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
9. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
10. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
11. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today ... co-development agreement with Therawis Diagnostics GmbH to develop and commercialize ... develop and market PITX2 as a marker to predict effectiveness ... cancer patients. "We are pleased to partner with ...
(Date:5/25/2016)... Va. , May 25, 2016  Granger Diagnostics ... sequencing test for wounds and infections. This test ... parasites, and select viruses. The test requires only ... David G. Bostwick , ... testing to facilitate wound healing: "We are excited ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... 2016 , ... Despite last week’s media reports hinting at a June rate ... until March 2017 for an interest rate increase, according to Rajeev Dhawan of the ... “The Federal Open Market Committee (FOMC) dot charts are of interest to the press ...
(Date:5/26/2016)... St. Louis, Missouri (PRWEB) , ... May 26, ... ... optimal cost, quality and clinical outcomes, hosted members and suppliers for its inaugural ... with a focus on their mission of elevating the operational health of America’s ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at ... offering a new model of care for living and healing, celebrated its grand opening, ... Life in a Real Home provided by Empowered Staff. , “This is an incredibly ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... to support the company’s continued investment and strategic growth plans in the Asia ...
Breaking Medicine News(10 mins):